Schering-Plough 1Q 1Q Revenues: $4.4 billion (-6%) 1Q Earnings: $805 million (earnings were $314 million in 1Q08) Comments: Pharmaceutical sales were down 5% to $3.4 billion, reflecting operational growth of 5% and an unfavorable impact from foreign exchange of 10%. Sales of Remicade were $518 million (+2%). Sales of Nasonex were flat at $306 million. Sales of Temodar were $247 million (+5%). Sales of Pegintron were down 4% to $216 million. Clarinex sales were $174 million (-19%). Sales...